


Ron Wacker, Mark Spengler, Michael Adler

Chimera Biotec GmbH, Emil-Figge-Str. 76a, 44227 Dortmund, Germany, Phone +49 231 9742 840, Fax +49 231 9742 844, info@chimera-biotec.com



The Immuno-PCR is an innovative biomarker detection and monitoring technology focused on the analysis of low abundant and hardly detectable biomarkers. It combines the advantages of immunoassays with the exponential signal amplification of PCR.


The Imperacer® product & service line enables the establishment of Immuno-PCR assays for any protein target.

Imperacer® can be used for any protein target

Imperacer® Key Advantages:

- Highest Sensitivity Available on the Market.
- Improved Quantification Ability.
- Extremely Low Sample Volumes.
- Compatible with the Matrix of Your Choice.
- Fast and Robust Assay Performance.


Biomarkers



in CSF

TNFα (green)
LOD: 10 fg/ml
QR: 6 logs

IL-6 (blue)
LOD: 100 fg/ml
QR: 6 logs



Inflammation Markers

throughout all research areas

in serum


Mouse IgG (blue)
LOD: 500 fg/ml
QR: 5 logs

Rabbit IgG (green)
LOD: 500 fg/ml
QR: 5 logs


in CSF

Aβ 1-40 (blue)
LOD: 250 fg/ml
QR: 5 logs

Aβ 1-42 (green)
LOD: 2.5 pg/ml
QR: 4 logs



Biomarkers



Therapeutics

Due to the high performance of Imperacer® this technology can improve the approach of e.g. the early diagnosis of Alzheimer's disease and prognosis of related dementias. Actually, Imperacer® is used for research and monitoring of Alzheimer's disease in the 2007 launched EU 6th framework Project "EDAR". However and furthermore, Imperacer® is applicable for any biomarker in the CNS field and beyond.

References:

- [1] Niemeyer, C.M., Adler, M., Wacker, R. (2007) Detecting antigens by quantitative immuno-PCR, *Nature Protocols*, 2(8), p.1918-1930
- [2] Adler, M., Wacker, R., Niemeyer, C.M. (2008) Sensitivity by combination: immuno-PCR and related technologies, *The Analyst*, 133, p.702-718
- [3] Wacker, R. (2007) Imperacer – New Prospects in CSF Biomarker Detection, *Neurodegenerative Diseases*, 4 (suppl 1), p.146